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Single nucleotide polymorphisma (TNF-α) is a potent immunomediator and proinﬂammatory cytokine that has
been implicated in the pathogenesis of a large number of human diseases. The location of its gene within
major histocompatibility complex and biological activities has raised the possibility that polymorphisms
within this locus may contribute to the pathogenesis of wide range of autoimmune and infectious diseases.
For example, a bi-allelic single nucleotide substitution of G (TNFA1 allele) with A (TNFA2 allele)}
polymorphism at −308 nucleotides upstream from the transcription initiation site in the TNF-α promoter
is associated with elevated TNF-α levels and disease susceptibilities. However, it is still unclear whether TNF-
α −308 polymorphism plays a part in the disease process, in particular whether it could affect transcription
factor binding and in turn inﬂuence TNF-α transcription and synthesis. Several studies have suggested that
TNFA2 allele is signiﬁcantly linked with the high TNF-α-producing autoimmune MHC haplotype HLA-A1, B8,
DR3, with elevated serum TNF-α levels and a more severe outcome in diseases. This review discusses the
genetics of the TNF-α −308 polymorphism in selected major diseases and evaluates its common role in
health and disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Tumor necrosis factor-alpha (TNF-α) is a proinﬂammatory cytokine
that produces left ventricular dysfunction, cardiomyopathy, pulmon-
aryoedemaand avariety of otherdiseases,whenover-expressed [1–2].
Recent observations showed that levels of circulating TNF-α are
elevated in patients with unstable angina, rheumatoid arthritis (RA)
and autoimmune disorders [3]. Although exact clinical signiﬁcance of
theseﬁndings is uncertain, given that TNF-α produces negative effects,
it has been postulated that the elaboration of this proinﬂammatory
cytokine may contribute to the progression of the disease process.
Important to the above hypothesis regarding the pathophysiological
role of TNF-α in disease is the elucidation of themechanisms bywhich
this proinﬂammatory cytokine exerts its effects. Although experi-
mental studies from a number of laboratories have begun to explore
the basic mechanisms of TNF-α at the tissue and cellular levels, until
recently polymorphism in the promoter region of the TNFwas found to
be linked with the genetic basis for these diseases.
Circulating TNF-α levels and their genetic associations between
gene polymorphisms are involved in many diseases and clinical
endpoints, e.g. rejection after heart, kidney and liver transplantationatata).
l rights reserved.and with a wide variety of other diseases [4–6]. The reasoning behind
the proposed involvement of TNF gene polymorphisms in diseases
either/or disease manifestations is that they may inﬂuence in-vivo
cytokine levels. This presumption is based on the observation that
individuals differ with respect to the level of cytokine production after
in vitro culture of their cells and that these differences may be
attributed partly to single nucleotide (SNP) or microsatellite poly-
morphismswithin its corresponding gene [7]. These associations have
not always been robust, replicable and consistent, for example some
studies could not show a relationship between TNFA −308 gene
polymorphism and liver graft rejection [8]. The generally held view is
that genetic factors may affect TNF-α levels and the location of TNF
locus is within the Class III region of the human major histocompat-
ibility complex (MHC; also known as TNFβ) on chromosome 6p21
conducive to its role in disease processes [9]. A number of SNP and
other polymorphisms have been identiﬁed in the TNF locus, some of
these have also been shown to inﬂuence the rate of transcription and
protein production of TNF-α and TNFβ associations with diseases [10].
In the light of these conﬂicting results we reviewed the literature of
available studies to clarify the role of −308 G/A polymorphism of the
TNF gene and the disease risk. There is explosion of information on the
disease associations with genetic polymorphism and it is impossible
to keep upwith published literature. We have listed the main research
studies on TNF −308 and disease associations with reference to
Table 1
Characteristics of published studies showing the associations between TNF-α genotyping and disease outcome
Subcontinent/
country
Population/
region
Design Disease group No. of subjects Findings Association Reference
Africa
Kenya Western
Kenyan Native
Observational Malaria 1048 children TNF2 homozygosity was
associated with preterm
birth, higher risk of death,
high density of
P. falciparum parasitemia,
and severe anaemia
TNF-308 promoter
polymorphism allele 2 is
a risk factor for early
childhood mortality and
malaria morbidity in
children
Aidoo M et al. [11]
South Africa Native Blacks Case control Systemic lupus
erythematosus
98 Reduced TNF-2 allele
level to disease
TNF-308 promoter
polymorphism is not an
independent risk factor
to SLE
Rudwaleit M
et al. [12]
Europe
Belgium Belgian
Caucasian
Non randomised
receiving inﬂiximab
treatment
Fistulizing and
non ﬁstulizing
Crohn's disease
226 patients+
128 Healthy
Frequencies for TNF-308
were not different for
responders and non
responders
TNF-308 promoter
polymorphism is not
associated with clinical
response to treatment in
Crohn's disease
Louis E et al. [13]
Sweden Natives Retrospective
analysis
Kidney transplants 157 patients Tendency towards a
increased risk of rejection
episodes and worse survival
in TNF-308/2 recipients
(pb0.02)
TNF-308/2 allele have
signiﬁcantly increased
risk for early graft
rejection
Wramner LG
et al. [14]
Goteborg Observational Heart transplant 70 patients Increased CAV and mortality
in Homozygous for TNFA
and TNFB
Positive association with
homozygous TNFA and
TNFB in morbidity and
mortality.
Ternstrom L
et al. [15]
Gothenburg Observational Coronary artery
bypass graft
surgery
86 CABG
patients
No difference observed
with allelic frequency and
TNF-α production
TNF-α gene
polymorphism does not
inﬂuence the postop
inﬂammatory process
Westerberg M
et al. [16]
Ireland Dublin Case control Meningococcal
disease
183 patients+
389 controls
Frequencies for TNF-308
were not different in
survivors and non survivors
TNF-308 promoter
polymorphism is not
associated with disease
outcome
Balding J et al. [17]
United
Kingdom
Edinburgh/
Scotland
Case control Acute pancreatitis 190 patients+
102 healthy
Frequencies for TNF-308
were not different in
patients and controls
Genetic factors are not
important in
determining TNF-α
secretion in patients
with Acute Pancreatitis
Powell JJ et al. [18]
Blackpool Case control Coronary artery
disease
One vessel (58),
multi-vessel (122),
normal et
coronaries (79),
healthy (250)
No signiﬁcant difference
in TNF-α 308 was found
between the groups
No correlation found
b.w TNFA 308 with the
development of CAD.
Allen RA et al. [19]
France Pessac Observational Coronary artery
disease
Male CAD (299) Genotype −308 G/A TNF-α,
A allele increase in unstable/
stable angina (p=0.029)
and not in MI
Conﬁrmation of crucial
role of TNF-α in
unstable angina
Bernard V et al. [4]
Germany Southern
Germany
Case control Ankylosing
spondylitis
96 patients+
58 healthy
Reduced TNF-308/2 allele
expression in patients
TNF-308/2 is protective
for AS in Southern
German population
Milicic A et al. [20]
Marburg Case control Chronic
obstructive
pulmonary disease
113 COPD, 113 CAD,
243 healthy
No signiﬁcant difference
in TNF-α 308, TNF-B, IL-6
and IL-10 b.w COPD and
counterparts
No correlation found
b.w TNFA 308 with
altered/abnormal
inﬂammatory response
Seifart C et al. [21]
Bonn Non randomised
receiving
immunosuppressive
therapy
Aplastic Anaemia 56 patients+
117 healthy
Positive response to therapy
among carriers of the
TNF2 gene
TNF-308/2 is contributes
to the pathogenesis and
therapeutic response
of AA
Demeter J et al. [22]
Bonn Clinical Coronary artery
bypass surgery
CABG on CPB 47;
CABG off pump 36
Homozygous TNF-B2 allele
had increase TNF-α levels
Strong association
reported
Schroeder S
et al. [23]
Spain Zaragoza Case control Peptic and
duodenal ulcer
130 DU+50 PU
patients+102
healthy
Reduced TNF-308/2
frequency in PU in
contrast to DU
TNF-308 allelic
distribution contributes
to the pathogenesis of
PU and DU
Lanas A et al. [24]
Tarragona Case control Type 2 diabetes 235 CAD patients
DM −ve; 106 CAD
DM +ve; 135 DM
CAD −ve, 207
health
− Gender difference +ve.
TNF-A/308 increased in CAD
and with or without DM than
controls (p=0.0056)
308 TNF-α gene
polymorphism
contribute to CAD risk
with DM
Vendrell J et al. [25]
Madrid Case control Celiac disease 157 patients+
305 Healthy
TNF-2 (A) was increased
in patients than controls
TNF-308 allelic
distribution contributes
to the pathogenesis of
Celiac disease
Fernandez L
et al. [26]
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Table 1 (continued)
Subcontinent/
country
Population/
region
Design Disease group No. of subjects Findings Association Reference
Asia
India Tamil Nadu/
Brahmin
Population
based study
Schizophrenia 86 unrelated trios Frequencies for TNF-308 A
allelic were not associated
with schizophrenic cases
TNF-308 promoter
polymorphism is not an
independent risk factor
to disease
Handoko HY
et al. [27]
China Chinese Han Case control Schizophrenia 314 patients+
340 healthy
Frequencies for TNF-308
G/A allelic were not different
in patients and controls
TNF-308 promoter
polymorphism is not an
independent risk factor
to disease
Duan S et al. [28]
Taiwanese Case control Type2 diabetic
mellitus
261 patients+
189 healthy
G-308 promoter
polymorphism and high
fasting plasma glucose levels
adjusted for age, sex, BMI and
diabetic status was found
TNF-308/2 genotype
might be more
susceptible to diabetic
complications
Shiau MY et al. [29]
Indonesia Sulawesi; ethnic
groups (Bugis,
the Makassans
and Torajans)
Population
based study
Parasitic infection 150 Bugis,
168 Makassans
and 58 Torajans
Signiﬁcant differences
exhibited at the TNF loci
TNF-308/2 (pb0.05)
Unique allelic
combinations with
potential to inﬂuence
cytokine secretion are
present in Sulawesi.
Lamsis F et al. [30]
Japan Tokyo and
Nagoya
Case control Schizophrenia 297 patients+
458 healthy
TNF-308GNA polymorphism
frequency of both the
patients and control are low
(1.5% and 0.8% respectively)
Japanese schizophrenics
are unrelated to the
−308GNA
polymorphism of the
TNF-α gene
Hashimoto R
et al. [31]
Korea Seoul Population
based study
– 80 individual from
20 normal Korean
families+133
unrelated healthy
controls
TNF-308 A were found more
frequently in Koreans (91.3%)
than Caucasians (pb0.001)
TNF microsatellite
haplotypes constitute a
highly polymorphic
system with possible
association with disease
process
Kim HK et al. [32]
Middle East Palestinian
and Jordanian
Case control Behcet's disease 102 patients+
115 healthy
TNF-308/2 allele
polymorphisms was not
raised in blind and non
blind subjects
A primary role of TNF-2
allele was not associated
with the development of
ocular disease
Verity DH et al. [33]
Oceania
Australia Australian
Caucasian
Case control Schizophrenia 65 patients+
151 healthy
Frequencies for TNF-308 A
allelic were not associated
with schizophrenic cases
TNF-308 promoter
polymorphism is not an
independent risk factor
to disease
Handoko HY
et al. [27]
Busselton Population
based study
Asthma 1004 subjects from
230 families
TNF-308/2 was more strongly
associated with disease
(p=0.002); showed
association with bronchial
hyperresponsiveness
(pb0.0001)and the use of
inhaled or oral steroids
(p=0.04)
Functional allele
TNF-308/2 might be
responsible for an
increased risk of asthma.
Moffatt MF
et al. [34]
Fiji Indigenous
Fijian
Case control Schizophrenia 134 patients+
92 healthy
Frequencies for TNF-308 A
allelic were not associated
with schizophrenic cases
TNF-308 promoter
polymorphism is not an
independent risk factor
to disease
Handoko HY
et al. [27]
North America
USA Alabama Clinical trial Rheumatoid
arthritis
457 subjects with
early RA
No association TNF-308 promoter
polymorphism is not an
independent risk factor
to disease
Hughes LB et al. [35]
Boston Prospective
observational
study
Asthma 708 children No association TNF-308 promoter
polymorphism does not
inﬂuence asthma
susceptibility
Randolph AG et al.
[36]
Dallas Observational Sepsis 159 patients
with burns
TNF-α −308 A allele
imparted 1.8 fold increase of
developing sepsis
Strong association of
TNF-α −308
polymorphism with
sepsis
Barber RC et al. [37]
California Prospective
observational
study
Sickle-cell
anaemia
230 children
with SCA
The combination of TNF −308
GG homozygosity was
associated with a particularly
strong predisposition to large
vessel stroke in SCA
TNF −308 play a role in
predisposition to
speciﬁc stroke subtypes
in children with SCA
Hoppe C et al. [38]
San Diego Case control Asthma Asthmatic (236)
and non
asthmatic(275)
TNF-α −308 A allele was
correlated with
asthma(pb0.04)
↑ risk of asthma with
TNF-a 308 ⁎ A
Witte JS et al. [9]
(continued on next page)
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Table 1 (continued)
Subcontinent/
country
Population/
region
Design Disease group No. of subjects Findings Association Reference
Mexico Mastizos Case control Rheumatic heart
disease with
Mitral valve
lesion and disease
87 patients+
101 healthy
MVD showed increased
frequency of −308 (AG) and
(A), while MVL showed
increased frequency of
−308 (A)
Distribution of −308
polymorphism was
similar in MVD and MVL
Hernandez-Pacheco
G et al. [39]
Mastizos Case control Systemic lupus
erythematosus
51 patients+
55 healthy
TNF-308 and genotype
distribution failed to show
any difference between
disease process and healthy
TNF-308 does not play a
any role in SLE
Zuniga J et al. [6]
South America
Brazil Native Prospective
observational
study
– 295 men+
389 women
Increased hs-CRP serum
levels in individuals
harbouring TNFA2 allele
(pb0.05)
Positive association of
disease with the
presence of TNFA2 allele
Araujo F et al. [40]
166 M.M. Elahi et al. / Biochimica et Biophysica Acta 1792 (2009) 163–172geographical regions in Table 1 [6,9,11–40]. In text, we discuss only the
main points and linkages published in the literature.
2. Biological regulation of TNF-α production and function
The biological functions of the TNF-α are varied and complex,
where on one hand it confers disease resistance and on the other
causes pathological complications. Indeed, TNF-α plays contradictory
role which may be related to genetic polymorphisms in the genes
regulating its production and effect. In the acute situation, local
production of TNF-α is clearly beneﬁcial. It increases the expression of
adhesion molecules on the vascular endothelium to allow immune
cells, in particular neutrophils andmacrophages, to translocate to sites
of tissue damage and infection [41]. Furthermore, TNF-α activates
phagocytes to engulf and clear infectious agents and cellular debris.
However, systemic or protracted exposure to TNF-α may be harmful.
High levels of circulating TNF-α are associated with toxic shock
induced by bacterial endotoxins [42] and derangements of metabo-
lism in surgery or trauma patients may be related to the cachetic
properties of this cytokine. The induction of interleukin-1 and
interleukin-6 production stimulated by TNF-α leads to elevated
temperature, sleepiness and the release of glucocorticoids [43].
These may be short-term value in combating certain infections, but
their long-term effects are likely to be detrimental.
TNF-α itself can suppress the production of more TNF-α, an effect
mediated through the TNFR1 and TNFR2 cell surface receptors for
TNF-α. Cells from mice deﬁcient of TNFR1 or TNFR2 produce
substantially more TNF-α upon stimulation. Although TNF-α may be
produced bymany cell types, macrophages are the main source of this
cytokine. TNF-α is produced as a membrane-bound 26 kDa molecule
from which is released the soluble 17 kDa active TNF-α molecule by
enzymatic cleavage. The enzyme involved is a metalloproteinase
disintegrin called TNF-α converting enzyme (TACE). Remarkably,
TACE also acts on membrane anchored TNFR2 protein thus controlling
the amount of soluble circulating TNFR2. This adds another layer to
the regulation of TNF-α function because soluble TNF receptor affects
the activity of TNF-α [44].
Studies of TNF-α function in genetically manipulated mice have
demonstrated that when homozygous TNF-α gene knockout mice (no
TNF-α production) were infected with the bacterium, Corynebacter-
ium parvum, there was little or no initial response but the mice went
on to develop a severe and fatal inﬂammatory reaction [45]. By
contrast, normal mice developed an inﬂammatory response that
resolved. This suggests that TNF-α has dual function, being proin-
ﬂammatory in the initial infection and then anti-inﬂammatory or
immunoregulatory in the later phases of the response. Heterozygous
mice, those with only one active TNF-α gene weremore susceptible to
endotoxin-induced shock and certain infections. In fact, in one strainof genetically manipulated mice deﬁcient in TNF-α production, an
arthritic condition akin to ankylosing spondylitis developed [46].
Again, these observations are consistent with a dual role for TNF-α,
acting as a proinﬂammatory agent to start with, but later having anti-
inﬂammatory or immunoregulatory functions. Indeed, recent studies
have shown that tumor necrosis factor alpha can autoregulate by
activating PIAS1 [protein inhibitor of activated STAT1 (signal transdu-
cer and activator of transcription 1)] SUMO E3 ligase through a SUMO-
dependent, inhibitor of kappaB kinase alpha (IKK alpha)-mediated
phosphorylation event. Once activated PIAS1 is then recruited to the
TNF-α gene promoter to repress transcription [47].
The TNF gene is located in close proximity to the HLA-B locus in
both humans and mouse. The 5′ ﬂanking region of the TNF gene
contains multiple potential regulatory sites, including consensus
sequences for the AP-1 and AP-2 sites, the cAMP-responsive element,
and sequences similar to the kappa B sequences found in immuno-
globulin and cytokine regulatory elements [48]. This sequence has
been demonstrated to be responsive to LPS and TNF stimulation. The
3′ untranslated region contains a sequence element affecting post-
translational control of TNF through mRNA stability and translation
efﬁciency. The functional importance and interactions of these
regulatory elements remain undeﬁned. Experimental evidence sug-
gests that phospholipase A2 and the lipoxygenase pathway may be
central in the process of TNF induction in leukocytes. Down-regulation
of TNF expression on the other hand is better understood. The
inhibition of expression appears to result from high levels of cAMP,
frequently induced through the action of PGE2. TNF secretion is
separately regulated and may involve the action of G binding proteins
[48]. In another study, posttranslational control of TNF-alpha release
in LPS-stimulated alveolar macrophages exposed to the stress
response was shown to be due to binding and sequestration by heat
shock proteins (HSP) [49].
3. TNF-α gene polymorphism and cytokine production
The TNF-α gene is located on the short arm of chromosome 6
within the major histocompatibility complex, where genetic altera-
tions in the TNF-α locus are now known to be involved directly in high
TNF-α production [10]. Several polymorphisms have been identiﬁed
inside the TNF-α promoter positioned at (relative to the transcription
start site) −1031 (T→C), −863 (C→A), −857 (C→A), −851 (C→T),
−419 (G→C), −376 (G→A), −308 (G→A), −238 (G→A), −162 (G→A),
and −49 (G→A), although those at positions −419, −163, −49 are rare
in Caucasians (Fig. 1). Among these variants, a polymorphism that
directly affects TNF-α expression is located at nucleotide position
−308. A single-base polymorphism within the promoter of the gene
for TNF-α results in 2 allelic forms, one in which guanine deﬁnes the
common allele (TNFA⁎1) and the other inwhich guanine is substituted
Fig. 1. TNF complex on chromosome 6, showing location of microsatellites and SNPs (see reference [11]).
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presence of the rarer TNFA⁎2 allele has been found to correlate with
enhanced spontaneous or stimulated TNF-α production in both in
vitro and in vivo [50].
SNP in the TNF-α gene itself are more likely to be of direct
functional signiﬁcance in terms of regulating TNF-α production, as
there are many SNP within the TNF-α gene promoter. In particular,
there is interest in those polymorphic sites in the regulatory regions of
the TNF-α gene that coincides with the DNA motifs to which
transcription factors bind. In vitro stimulation of TNF-α production
by cells from −308⁎G/G homozygous individuals and G/A hetero-
zygote individuals have produced conﬂicting results. Two studies have
reported higher TNF-α production by cells fromG/A donors than by G/
G cells [51]. Other studies have reported no signiﬁcant affect [52–53].
However, it is interesting to note that these studies used different LPS
concentrations and the number of individuals with the G/A genotype
studied was in most of the cases small, affecting the power of the
study to detect any signiﬁcant difference between the genotypes.
Gene reporter assays have been employed to investigate the −308
SNP and again, contradictory results were reported. It was suggested
that the A allele does inﬂuence TNF-α gene transcription [8] while
others have concluded that it does not [54]. There are many variables
affecting the results of this type of experiments; including the length
of the promoter sequence used, the presence or absence of the 3′ UTR,
the cell type used for transfection, and whether it is of human or non-
human origin. Different studies have used different approaches, thus
making it difﬁcult to draw a general conclusion. So far, evidence
suggests that circulating TNF-α levels do not seem to correspond with
the −308 TNF promoter polymorphisms. However, although circulat-
ing TNF-α level might be under a multifactoral regulatory process,
local TNF-α concentration might be of greater importance and under
more control by speciﬁc polymorphisms [55].
An analysis of the evaluation of the extended MHC haplotypes
including the TNF region has been presented recently in which it was
proposed that there are three ancient extended haplotypes from
which the complex modern haplotypes were derived by mutation or
crossover. In this analysis, the −308⁎G, −238⁎G haplotype was
generally associated with low TNF-α production while either the−308⁎ A allele or the −238⁎A allele were associated with high TNF-α
production [56].
However, there are many biological steps, apart from the inﬂuence
of the gene polymorphisms on TNF-α production, for which the
control, production and release of TNF-α and its activity are regulated.
4. Genetic associations between TNF −308G/A polymorphisms and
disease
The polymorphism in the humanTNF-α gene encoding high TNF-α
levels may be important in the susceptibility or severity of diseases
and in other inﬂammatory conditions as discussed below.
4.1. TNF-α genotypes in parasitic, bacterial and viral infections
In parasitic infections, the −308⁎A allele has been associatedwith a
fourfold increase in risk for cerebral malaria and a sevenfold increase
in risk for development of serious neurological consequences [57].
This association was shown to be independent of the inheritance of
HLA antigens. A similar study conﬁrmed the association with the
−308⁎A allele in the population of Sri Lanka [58] whereas in the West
Africans the −376 alleles are in strong positive linkage disequilibrium
with the −238 alleles and in strong negative linkage disequilibrium
with the −308 alleles [59]. Furthermore, the −376⁎A allele was found a
risk factor independent of the −308⁎A allele for the development of
cerebral malaria. Taken together, these results suggest that there are
two genetic effects operating independently, however, its mechanism
is yet unclear.
The −308⁎A allele was also associated with the most severe
outcome, mucocutaneous leishmaniasis [60]. Hence both the risk of
infection and its coursemay be associated with polymorphisms in TNF
gene. In multiple injured patients with severe sepsis the TNFA⁎2 allele
acts as a predictor of severe post traumatic sepsis and increased levels
of circulating TNF-α [61–62]. It is interesting to note that the −308⁎A
allele has been associated with severe septic shock and death. Several
studies have investigated the association between TNF alleles and viral
infections. The −238⁎A allele was associated with chronic infection
with hepatitis B virus. No similar ﬁndings were found for −308
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C virus infection, the −238⁎A allele being associated with chronic
hepatitis while the −308 alleles were not [64]. A comparison of
Cytomegalovirus (CMV) positive and negative healthy adults showed
that the frequency of the TNF-α −308⁎A allele was slightly increased
in the seronegative individuals [65]. However, this reached statistical
signiﬁcance only when the genotype of another cytokine that
inﬂuences the inﬂammatory response, interleukin-1 receptor antago-
nist was taken into account.
4.2. TNF polymorphisms and autoimmune diseases
In autoimmune diseases, TNF-α is one of the most studied genes.
As most autoimmune diseases are associated with HLA, results of TNF
polymorphism studies could be interpreted by linkage disequilibrium
with HLA or, vice versa.
4.2.1. Systemic lupus erythematosus
In systemic lupus erythematosus (SLE), there is an associationwith
−308⁎A allele and also a strong associationwith the HLA-DR3 antigen.
The association between SLE and TNF genotype might best be
explained by the strong linkage disequilibrium between the −308⁎A
allele and the HLA-A1, B8, DR3 haplotypes. The TNF-308⁎Awas shown
to be associatedwith SLE in this ethnic group independent of any HLA-
DR associations [66].
4.2.2. Rheumatoid arthritis
In rheumatoid arthritis (RA) joints, there is an abundance of TNF-α
so it was predicted that TNF-α gene polymorphism is associated with
the disease. Further analysis found no association between the −308
alleles and RA. There is an association between HLA-DR4 and RA but
there is a lack of linkage disequilibrium between the TNF-308
polymorphism and this HLA antigen. More recently, other TNF-SNP
polymorphisms have been shown to correlate with the severity of RA
but not with the initial susceptibility to the disease [3]. In order to
better understand the genetic background of juvenile rheumatoid
arthritis (JRA) several studies have been carried out recently. A study
by Date et al. [67], demonstrated that the −857T allele of the TNF alpha
gene which was related to high production of tumor necrosis factor
alpha, was associated with systemic JRA and that the −857T allele may
enhance the effect of the DRB1⁎0405/DQB1⁎0401 haplotype in
predisposing to the development of systemic JRA. Ozen et al. [68],
studied a group of 51 Turkish JIA patients and a second group
consisted of 159 JIA patients from the Czech Republic. Healthy
individuals (93 and 100) from each country served as controls. In
both JIA cohorts, the distribution of genotypes was not signiﬁcantly
different among the types of JIA. The G→A −238 polymorphism did
not have an effect on the patients' outcome in either group. The G→A
−308 polymorphismwas signiﬁcantly associated with a poor outcome
in the Turkish group (p=0.005) but not in the Czech patients. Another
recent study examined the association of multiple TNF SNPs with
juvenile oligoarthritis by constructing and analysing SNP-tagged TNF
haplotypes [69]. A total of 144 simplex families consisting of parent
and affected child, as well as 88 healthy, unrelated control subjects
were available for study. In these individuals, 9 polymorphic positions
of TNF were typed by a high-throughput genotyping method based on
the SnaPshot assay. The results demonstrated that TNF locus is linked
and is associated with juvenile oligoarthritis and that information on
the htSNPs can be useful in genetic studies of diseases in which TNF
may be of relevance. In addition, a study by Schmeling et al. [70] on
Caucasian subjects on TNF-alpha promoter polymorphisms at posi-
tions −163, −238, −244, −308, and −376 determines the association
with disease in 228 patients with JIA and 196 healthy individuals.
Genomic DNAwas isolated and a PCR fragment of about 500 base pairs
of the TNF gene promoter were ampliﬁed by PCR. Detection of
polymorphisms was achieved by a single sequencing procedure. Theresults demonstrated that TNF promoter polymorphisms may play a
role in the pathogenesis of JIA. The TNF-238A allele seems to be
associated with juvenile psoriatic arthritis. The TNF-308A allele is less
frequently found in rheumatoid factor negative but not in rheumatoid
factor positive polyarthritis and may therefore be associated with a
more severe disease, while themore commonTNF-308G allele may be
protective.
As the pathophysiology of RA becomes better understood, new
therapeutic strategies and agents have been developed [71]. The
efﬁcacy of early and aggressive treatment with disease-modifying
anti-rheumatic drugs (DMARDs) has now been studied. DMARDs,
such as methotrexate (MTX), sulfasalazine (SSZ) and leﬂunomide,
have documented prevention of the structural damage of the joints
[72–73]. Recently, biologic response modiﬁers targeting speciﬁc
cytokines, such as tumor necrosis factor- (TNF-) or interleukin-1,
have been introduced, and the results indicated the effective
suppression of the RA activity. However, the outcome of the treatment
with DMARDs in RA patients is known to vary among patients. Recent
advances in genetics have clariﬁed that these individual differences
are based on genetic polymorphisms, and this knowledge has
encouraged the application of pharmacogenetics to the treatment of
RA. The difference in the response has been reported in biologic
response modiﬁers and that in the case with the tumor necrosis factor
(TNF) blocking agents, 20–40% of patients have been described as non-
responders [74]. A recent study by Padyukov et al. [74] analysed
whether polymorphisms of several cytokine genes are associated with
the responsiveness toTNF blockadewith etanercept. 123 patients with
active RA were treated with etanercept and response rates were
determined after three months using American College of Rheuma-
tology (ACR)20 and disease activity score (DAS)28 response criteria.
Genotyping was done for TNF (−308 TNFA), interleukin (IL)10 (−1087
IL10), transforming growth factor (TGF)beta1 (codon 25 TGFB1), and IL1
receptor antagonist (intron 2 IL1RN). The results indicated that 24
patients (20%) were deﬁned as non-responders owing to their failure to
fulﬁl any of the ACR20 or DAS28 response criteria. None of the recorded
alleles was alone signiﬁcantly associated with responsiveness to
treatment. However, a certain combination of alleles (−308 TNF1/TNF1
and −1087 G/G) was associated with good responsiveness to etanercept
(pb0.05). In addition, a combination of alleles inﬂuencing interleukin 1
receptor antagonist (IL1Ra) and TGFbeta1 production (A2 allele for
IL1RN and rare C allele in codon 25 of TGFB1 gene) was associated with
non-responsiveness (pb0.05). The study concluded that genetic poly-
morphisms, which may inﬂuence the balance of pro- and anti-
inﬂammatory cytokines of relevance for the course of RA, are associated
with clinical responsiveness to etanercept treatment.
4.2.3. Ankylosing spondylitis
On the other hand, tumor necrosis factor-alpha also has a
prominent role in the inﬂammatory process and bone resorption in
patients with ankylosing spondylitis (AS). Indeed, a recent study by
Woo et al. [75], evaluated the markers of clinical efﬁcacy and bone
biochemical changes in Korean patients with AS treated with
etanercept therapy. The authors demonstrated that in patients with
AS, etanercept therapy may be effective at reducing disease activity
and improving bone biochemical markers and that matrix metallo-
proteinase 3 (MMP-3) may be a useful biomarker for monitoring
etanercept therapy. Indeed, changes in MMP-3 had a high correlation
coefﬁcient with changes of C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) upon etanercept treatment (CRP, r=0.446,
p=0.022; ESR, r=0.449, p=0.021). In another study [76] by Maksy-
mowych et al., where the authors determined whether a vertebral
corner that demonstrates an active corner inﬂammatory lesion (CIL)
on magnetic resonance imaging (MRI) in patients with AS is more
likely to evolve into a de novo syndesmophyte visible on plain
radiography than is a vertebral corner that demonstrates no active
inﬂammation on MRI. MRI scans and plain radiographs were obtained
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of anti-tumor necrosis factor alpha (anti-TNF-alpha) therapy. New
syndesmophytes developed signiﬁcantly more frequently in vertebral
corners with inﬂammation (20%) than in those without inﬂammation
(5.1%) seen on baseline MRI (pb/=0.008 for all reader pairs). They also
developed more frequently in vertebral corners where inﬂammation
had resolved than in those where inﬂammation persisted after anti-
TNF treatment.
However, studies are divided as to whether TNF-alpha polymorph-
isms play a role on the pathogenesis of spondyloarthritis conditions.
Earlier ﬁndings by Verjans et al. [77] and Fraile et al. [78] found no
direct evidence to suggest TNF-alpha polymorphisms have an
independent effect on AS susceptibility. In addition, Kaijzel et al.
[79] concluded in their study that an association between TNF-238G
and AS is secondary to the HLA-B27 gene and that TNF-238 and TNF-
376 alleles are not likely to be independently involved in the
susceptibility to AS. In contrast, similar study by McGarry et al. [80],
showed −308 TNF-alpha gene allele-1 was signiﬁcantly increased in
patients with AS. Another study by Rudwaleit et al. [81] showed that
in HLA-B27 positive AS subjects, TNF-alpha gene 1/2 heterozygosity at
−308 was associated with a higher percentage of TNF-alpha produc-
tion and T cell numbers as compared with TNF-alpha gene 1/1
homozygosity. Vargas-Alarcon et al. also demonstrated that TNF-alpha
−308 promoter polymorphism was associated with the genetic
susceptibility to undifferentiated ankylosing spondylitis [82] with a
similar pattern was also observed in AS patients in a study by Shiau et
al., in Taiwan [83]. A more recent study by Lu et al. [84], demonstrated
that HLA-A33-B58-Cw10 haplotypes associated with TNF-alpha
promoter −308(G/A) polymorphism might play an important role in
disease pathogenesis of AS in Chinese population partially related to
increased TNF-alpha production.
The therapeutic options for patients suffering from severe forms
of spondyloarthritis (SpA) have been rather limited in recent decades.
However, there is now accumulating evidence that anti-TNF therapy
is highly effective in SpA, especially in ankylosing spondylitis (AS)
and psoriatic arthritis (PsA) and that this treatment seems to be even
more effective than the same therapy in rheumatoid arthritis (RA)
[85]. There is however, little evidence to suggest that TNF-alpha
genetic diversity plays a role in the effectiveness of currently
available anti-TNF treatments. Much of this information is discussed
in a greater detail in the recent manuscript by Braun et al. [85]. In
brief, the anti-TNF-alpha agents currently available, inﬂiximab
(Remicade); Centocor), etanercept (Enbrel); Amgen) and adalimumab
(Humira; Abbott), are approved for the treatment of RA in the US;
inﬂiximab and etanercept are approved in Europe. The situation in
SpA is different to RA because there is an unmet medical need,
especially in AS, since no therapies with disease-controlling anti-
rheumatic drugs are available for severely affected patients, espe-
cially with spinal disease. Thus, TNF blockers might even be
considered as ﬁrst-line immunosuppressive agents in patients with
active AS and PsA who are not sufﬁciently treated by non-steroidal
anti-inﬂammatory drugs and sulfasalazine, if peripheral arthritis is
present. For inﬂiximab, a dosage of 5 mg/kg at intervals between 6
and 12 weeks was necessary to constantly suppress disease activity;
this is also a major aim of long-term treatment. No dose-ﬁnding
studies have yet been performed. The standard dose of etanercept is
25 mg s.c. twice-weekly. No studies on adalimumab (standard RA
dose 20–40 mg s.c. every 2 weeks) have yet been conducted in SpA.
The efﬁcacy of etanercept was ﬁrst demonstrated in PsA and
etanercept is now approved for this indication. A double-blind
study has also been performed in AS, with similarly clear-cut efﬁcacy
[85]. There is preliminary evidence that both agents do also work in
other SpA such as undifferentiated SpA.
Insulin dependent diabetes mellitus (IDDM) is strongly associated
with the inheritance of the HLA DR3 and DR4 antigens. Studies of SNP
have revealed weak associationwith the TNF-308⁎A allele, but in eachstudy this could also be attributed to linkage disequilibriumwith HLA-
DR3 [86]. Similarly, the investigation of the TNF genotypes in Type II
diabetes have demonstrated that 308 TNF-α gene polymorphismmay
contribute to CHD risk in patients with type-2 diabetes and it could
constitute a useful predictive marker for CHD in type-2 diabetic
women [25].
Multiple sclerosis (MS) is a demyelinating disease of the central
nervous system associated with HLA DR2 in North Europeans and
North American Caucasians [87]. The TNFA −308 polymorphism was
investigated by several groups, [88–89] none of these studies showed
any signiﬁcant association with MS.
4.3. TNF polymorphisms and transplantation
Biopsies from rejecting kidney or heart transplants show the
presence of an inﬂammatory inﬁltrate of cells capable of producing
TNF. Studies in kidney [14], heart transplant recipients [15] and liver
[88] transplant recipients revealed an association between TNFA −308
polymorphisms and acute rejection. Death of heart transplant
recipients as a consequence of irreversible acute rejection of their
graft is exclusively conﬁned to those of the TNFα-308⁎A genotype.
4.4. TNF-α genotype in inﬂammatory conditions
Inﬂammation is a major component of a range of diseases. A TNFA
−308⁎allele association is evident in the liver disease primary sclerosing
cholangitis [89]. Equally, in primary biliary cirrhosis there was shown to
be an association with the TNF −308⁎ A allele shown in a group of
Scottish patients awaiting liver transplants [90]. In addition, there are
several inﬂammatory conditions of the gastrointestinal tract such as
andomandCrohn's disease [13] that showapositive associationwith the
−308⁎A allele, although the last is very weak. By contrast, in ulcerative
colitis the −308⁎A allele seems to have a protective effect [91].
4.5. TNF-α genotypes in cancer
The inﬂuence of cytokine genotype on susceptibility to cancer or its
prognosis has been considered. The areas looked at have been cancers
of the immune system such as Non-Hodgkin's lymphoma where the
TNF-308⁎A and LT-α Nco1⁎1 alleles were found to be related to overall
survival and progression free survival [92]. In chronic lymphocytic
leukaemia again, the TNF-308 alleles were associated with the disease
[93]. Hence high TNF production may promote the condition leading
to the development of cancer, an indirect susceptibility factor for these
diseases.
4.6. TNF-α genotypes in coronary artery disease
Coronary artery disease (CAD) is both multifactorial and polygenic
in nature with atheroma formation, the pathological hallmark. CAD is
an inﬂammatory process, with proinﬂammatory cytokines, such as
TNF-α, having a major role in its pathogenesis [19]. Through its effects
on lipid metabolism, insulin resistance and endothelial function, TNF-
α is reported to be involved in the CHD. While some reports have
suggested that −308 TNF-α gene polymorphism may contribute to
CHD risk in patients, [4] others have found no evidence of inﬂuence on
the CHD outcome [16].
4.7. TNF-α polymorphisms and restenosis in coronary artery disease
Restenosis is still the main drawback of percutaneous transluminal
coronary angioplasty (PTCA) [94]. It is thought to be multi-factorial
process where recoil of the vessel, neointimal proliferation and
thrombus formation are thought to play a role. Until now it has proved
difﬁcult to predict restenosis on clinical and procedural grounds,
however, genetic epidemiology might provide more insights.
Fig. 2. Summary of the molecular nutrition hypothesis.
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predominantly known for its powerful proinﬂammatory effects
[3]. In response to different stimuli such as mechanical injury of
the arterial wall caused by stent deployment, a local inﬂammation
is elicited that is characterised by adhesion and invasion of
inﬂammatory cells. Tight control of gene activity and protein
production may equilibrate the pro and the anti-inﬂammatory
potentials of TNF-α and in turn prevent excessive inﬂammation
and limit neointima formation [95]. However, imbalances in the
regulation of this system may interfere with anti-inﬂammatory
effects and stimulate proinﬂammatory activities that result in
neointima formation and restenosis. The genes encoding TNF-α
contain variable sites that may be associated with different
responsiveness to regulatory signals. In particular SNP located in
the promoter regions of the TNF-α gene (−308G/A) were found to
differentially affect binding of nuclear transcription factors, tran-
scriptional activity and/or protein production, [8,52] characteristics
that may be related to the unfavourable outcomes after coronary
interventions.
5. Effect of TNF-α promoter on transcriptional activation
Studies have suggested that the polymorphism at −308 has a
signiﬁcant effect on transcriptional activity in reporter gene assays
and that this could explain the association between the high TNF-α
phenotypes and the DR3 haplotype [8]. The molecular mechanism of
this difference is not completely clear because no evidence was
reported of a major difference in afﬁnity of the DNA-binding protein(s)
to the two allelic forms of the TNFA promoter. Perhaps as a result of
difference in the DNA/chromatin structure at the polymorphic site, the
interaction of transcription factors is enhanced leading to stronger
transactivation of the TNF-α gene. Interestingly, a homologous
sequence in the TNFA promoter (−254 to −230) has been shown to
bind a transcriptional repressor and not AP2 [96]. It may be, therefore,
that a novel protein binds to the polymorphic TNFA −308 site and
evidence obtained from a study using both Jurkat and U937 cells has
demonstrated binding of a novel protein only to the TNF2 allele [96]. A
relatively recent study of TNF-α production from peripheral blood
mononuclear cells stimulated with anti-CD3 and anti-CD28 has
shown a higher TNF-α production phenotype in TNF2 carriers, and
of two TNF haplotypes, differing only at −308, the TNF2 +ve haplotype
produced signiﬁcantly more TNF-α [74]. There is, therefore, evidence
that the TNF2 genotype is associated with increased TNF productions
in vitro.
6. TNF-α gene polymorphism association in the
nutrition-inﬂammation axis
The success of the Human Genome Project and the powerful
tools of molecular biology have ushered in a new era of medicine
and nutrition. This new era of molecular nutrition-that is, nutrient-
gene interaction can unfold in dichotomous directions. One could
focus on the effects of nutrients or food bio-actives on the
regulation of the gene expression (i.e. nutrigenomics) or on the
impact of variations in gene structure on one's response to nutrients
or food bio-actives (i.e. nutrigenetics). In a simple classiﬁcation of
nutritionally modiﬁable genes as being either constitutive or
inducible, it is the second order classiﬁcation of these same genes
as being either wild type or polymorphic that underlies the highly
variable response of humans to a given diet (Fig. 2). In order for
TNF-α SNP to be a practical signiﬁcance in the nutrigenetics
paradigm, the SNP is likely to present with the number of
characteristics such as exhibiting a high frequency in the general
population of interest modifying or regulating proteins at the top of
biological cascades or a rate limiting steps in intermediary
metabolism and having attendant biomarkers that provide surrogatemeasures of clinical effect. At the present time there are only a few
SNP that meet the criteria but from those that do we can learn a
great deal.
7. Conclusions
Overall, TNF-α has been shown to be an important pro-inﬂamma-
tory cytokine in disease and health. It is difﬁcult to make general
statements about the associations of TNF polymorphisms and TNFα
production or pathology. The TNF polymorphisms are found in a region
of great polymorphic variation and they are in linkage disequilibria
with the HLA genes and with each other. Because of differences in the
distribution of HLA alleles one might expect variation in associations
between TNF polymorphisms and various conditions in different
geographical areas. Indeed, there is a geographical variation in the
frequency of the −308⁎A allele. It is present in approximately 5% of the
population of South Africa compared with 30% in white Caucasians in
the United Kingdom. Specimens from blood donors of regionally
subdivided British population demonstrated signiﬁcant differences
exit among the subgroups of the population and it is argued that these
may be involved in the invariable responses experienced in disease
process [97].
Given the biological regulation of TNF-α and its role in the
inﬂammatory process, it is perhaps surprising that the genetic
inﬂuences on cytokine production have much inﬂuence on disease
processes and their outcome. The associations between TNF-α
genotype and disease are not absolute as suggested by different
conﬂicting studies (Table 1). Nevertheless, it is clear that the genetic
regulation of TNF-α at sites of inﬂammation is important. Under
circumstances where the release of TNF-α has been triggered the
genetically endowed capacity for greater TNF-α production leads to
more severe inﬂammatory reactions.
Given the relationship between TNF-α genotype and disease, the
prognostic value of TNF-α genotyping is obvious, particularly in
situations such as organ-transplantation where knowledge of the
likely immune response to the graft may lead to modiﬁcation of the
immunosuppressive regimen. Other applications are readily foresee-
able, too, so that genotyping for TNF-α polymorphisms is likely to be
useful in many areas of medicine. To understand our personal
uniqueness, nutrigenomics SNP is likely to open the door to the
management and optimisation of our health through tailored
nutrition. Clearly this is a lofty and distant goal; equally true is the
fact that we have already started the journey towards it.
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